Connect with us

Cannabis

Former Coors CEO turned cannabis player says “virtually all“ big alcohol companies aiming at MJ sector — Part 2

Published

on

 (FinancialPress) — Part 2 of the interview given by Torsten Kuenzlen, former CEO of Molson Coors and executive for Coca-Cola who has chosen to incurse into the legal cannabis industry.
Kuenzlen believes “there can be no doubt“ on the prospect of future tie-ups between big alcohol and cannabis companies:
“We know that virtually all alcohol companies are very carefully looking at the cannabis space and looking to partner in some shape or form. Those shapes can be anything from innovation alliances with pharma and nutraceuticals – and all the way to partial ownership.

Today, alcohol companies are buying cannabis companies. We will see a time when cannabis companies start buying alcohol companies. Definitely within the next three to five years“

Regarding legalization in the United States, and if he believes it will happen:

“In my mind, it’s a question of when, not if, federal legalization will come south of the border.

So the opportunities to build great brands, innovation and capabilities north of the border for the day it becomes federally legal in the states is a monster opportunity for Canada.“

On the possibility of expansion to international markets, and a global-level product standardization:

“In terms of building global brands, we believe we can build the Absolut Vodka or Coca-Cola equivalent of cannabis.

When you fast-forward 10 years, consumers will be able to be anywhere in the world, and they will be able to buy a brand that has the consistent experience they expect.“

With the cannabis industry receiving bigger and bigger players into its fold, it‘s up to each investor‘s imagination and research to figure how big the industry can get. Not only that, but to informedly identify which companies are forming the best teams to properly exploit the surge of opportunities that come with the development of a brand-new industrial sector.

Breaking

EVIO Opens Additional Cannabis Revenue Streams with Keystone Lab’s Expanded Approval in Canada

Published

on

(FinancialPress) – Coming October 17, the watershed moment of legal marijuana across Canada is closing in quickly. The anticipation is providing a positive effect on stocks in the industry after months of stagnation. It is also leading to important changes for select companies, such as expanded licensing for Edmonton’s Keystone Labs by Health Canada, widening the opportunities for the lab to generate revenue and create new products.

Keystone Labs is 50% owned by EVIO Canada, a unit of EVIO Inc. (OTCQB:EVIO), one of the largest public companies in North America providing cannabis testing and scientific research for the regulated cannabis industry. Gathering momentum from the updraft in cannabis stocks lately, shares of EVIO have risen over 60% from an 8-month low in the last four weeks.

On Monday, EVIO said that Health Canada approved an amendment to Keystone’s existing Dealer License that expanded the lab’s product and service offerings. With the modification, Keystone can manufacture, process, package, label, and sell cannabis related products to Licensed Producers (LPs) and Licensed Distributors (LDs) throughout Canada.

There are several other important distinctions that come with the approval, including allowing the lab to work with Canadian LPs as a contract manufacturer of approved cannabis products, as well as perform R&D activities to develop new extraction methods and product formulations.

Furthermore, Keystone can now legally transport or send cannabis in many forms, ranging from experimental raw materials to finished goods, to customers and partners across the country. This distinction provides Keystone with a competitive edge and avenue for vertical growth, as there are only a select group of Canadian labs with this logistic capacity.

The approval “will allow Keystone Labs to partner with other third-party test labs to outsource testing that we currently offer our clients and vice versa,” said the company in a press release on the expanded capabilities.

EVIO’s CEO William Waldrop added, “Being able to manufacture and start product development will accelerate our growth by building strategic partnerships and in anticipation of Canadian legalization. This will generate additional revenue for Keystone Labs along with its analytical testing and R&D.”

Fact is that Canada is gearing-up to initiate the global cannabis market by becoming the first industrialized country to legalized adult-use of the plant. The change in legislation has set the cannabis industry on fire again, as measured by the Horizons Marijuana Life Sciences Index ETF (TSX: HMMJ) recently topping $1 billion in assets and U.S.-listed ETFMG Alternative Harvest ETF (NYSE American: MJ) being the best performing exchange traded fund in August (and still rising).

Against this backdrop, EVIO Labs continues to position itself as a North American leader in the lab space, a market that remains underappreciated as an essential component of the industry.

Continue Reading

Breaking

Canada, it‘s official: legal cannabis set for October

Published

on

(FinancialPress) — Canada‘s Prime Minister, Justin Trudeau, has officialized the date for countrywide legalization of marijuana. Starting on October 17th, Canadians legal cannabis will be the norm for commercialization and consumption.

Trudeau‘s revelation ended months of mystery over which would be the specific date in which the new policy would come into effect. Initially slated for July 1, the bill encountered several last-minute oppositions that led to its enactment being delayed further.

He had originally promised 8 to 12 weeks for businesses, provinces and municipalities to set the framework to receive the legalization. The new date gives them 17 weeks.

The polemic Bill C-45, which regulates how legalization of recreational weed will occur, was passed in its final vote this week. While some congressmen declared it a “historic“ event, many others were cautious about all the work left to be done after a major public policy overhaul.

Now, the bill awaits royal assent; which should happen in a few days‘ time at most. However, that will not effectively enact the new policy immediately, but is rather another step in that direction.

What we know

Provinces and territories have full jurisdiction over where and how legal cannabis products can be commercialized. This has led to an array of private, licensed and government-run stores and facilities across the country.

The legal age of purchase and consumption has been set to 19, with the exceptions of Quebec and Alberta where it will be 18. Consumers will also be able to purchase the plant online.

Regulation over where Canadians can consume the drug will be strict, and is still pending announcement.

Legal cannabis products will be sold in plain packaging. Fresh/dried weed, seeds and oils will be commercially available immediately after the set date; edibles, however will take longer to be rolled out – and are not expected in shelves before early 2019.

Canada thus becomes the second nation to roll out countrywide legalization, following Uruguay.

 

Continue Reading

Breaking

Judge double OKs sale of smokable medical cannabis in Florida

Published

on

(FinancialPress) — A ban on smokable medical marijuana was lifted by a Florida judge. The decision opens a massive potential for the Sunshine State‘s medical cannabis market.

Judge Karen Gievers (Leon County Circuit Court) upheld a previous ruling that declared that the Florida Legislature‘s ban on smokable MMJ is inconstitutional.

She added that continuing to delay her ruling would ultimately cause irreparable harm to patients in need of the administration method. The ban will be officially lifted on June 11.

Her original ruling was contested by the state‘s health department – which automatically put her decision on ice.

“First, they cannot legally access the treatment recommended for them,” the ruling said. “Second, they face potential criminal prosecution for possession and use of the medicinal substance.”

During the hearing, Gievers went more in-depth:  “there is no evidence the defendants [the state] will suffer harm if the stay is vacated. Lifting the stay preserves the status quo by returning the law to its previous state as it existed following the 2016 adoption” of the constitutional amendment.

In response, the health department‘s spokesperson, Devin Galetta, said : “The use of medical marijuana is outlined in state law, which was passed by an overwhelmingly bipartisan majority of the Florida legislature. Our focus remains with ensuring that patients have access to medical cannabis, and the Florida Department of Health has made significant progress in making this treatment available. In fact, there are more than 117,000 patients who have access to medical marijuana and over 1,300 doctors are licensed to order this treatment.”

Continue Reading

Most Popular